Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Health Catalyst (HCAT) Liabilities and Shareholders Equity (2018 - 2025)

Health Catalyst (HCAT) has disclosed Liabilities and Shareholders Equity for 8 consecutive years, with $587.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Liabilities and Shareholders Equity fell 27.79% year-over-year to $587.1 million, compared with a TTM value of $3.0 billion through Sep 2025, up 1.79%, and an annual FY2024 reading of $858.9 million, up 22.39% over the prior year.
  • Liabilities and Shareholders Equity was $587.1 million for Q3 2025 at Health Catalyst, down from $616.2 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $891.5 million in Q1 2025 and bottomed at $563.0 million in Q2 2021.
  • Average Liabilities and Shareholders Equity over 5 years is $737.9 million, with a median of $752.3 million recorded in 2022.
  • The sharpest move saw Liabilities and Shareholders Equity skyrocketed 85.01% in 2021, then decreased 27.79% in 2025.
  • Year by year, Liabilities and Shareholders Equity stood at $832.1 million in 2021, then decreased by 9.59% to $752.3 million in 2022, then dropped by 6.71% to $701.8 million in 2023, then grew by 22.39% to $858.9 million in 2024, then crashed by 31.64% to $587.1 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for HCAT at $587.1 million in Q3 2025, $616.2 million in Q2 2025, and $891.5 million in Q1 2025.